| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H11ClN4O2S |
| Molecular Weight | 334.781 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(C=C1)S(=O)(=O)NC2=CN=C3C(Cl)=CC=CC3=N2
InChI
InChIKey=CTSNHMQGVWXIEG-UHFFFAOYSA-N
InChI=1S/C14H11ClN4O2S/c15-11-2-1-3-12-14(11)17-8-13(18-12)19-22(20,21)10-6-4-9(16)5-7-10/h1-8H,16H2,(H,18,19)
| Molecular Formula | C14H11ClN4O2S |
| Molecular Weight | 334.781 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chlorsulfaquinoxaline is a halogenated derivative of sulfaquixonaline, an immunosuppressive and antifungal agent used in the control of coccidiosis in poultry, rabbit, sheep, and cattle. In vitro, Chlorsulfaquinoxaline acts as a topoisomerases IIα and IIβ poison, thus inhibiting DNA replication. Chlorsulfaquinoxaline shows good activity against human tumor cells in the human tumor colony-forming assay and subsequently has shown activity against murine and human solid tumors. No major objective antitumor responses was observed during Chlorsulfaquinoxaline Phase II clinical evaluation in non-small-cell lung cancer and metastatic colorectal cancer. Chlorsulfaquinoxaline was well tolerated with hypoglycemia being the most clinically significant toxicity.
